Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

Completed · Not applicable · Has a placebo group

Conditions studied: Osteoporosis

In brief

Teriparatide is a potent osteoporosis medication that helps prevent fractures, however, the investigators know little about its effect on the hip. The investigators will evaluate hip bone samples from patients treated with teriparatide before undergoing hip replacement. The information will help us understand how teriparatide might help reduce hip fracture risk.

Key facts

Study ID

NCT01309399

Run by

Health Research, Inc.

People needed

40

Starts

2010-08-01

Expected to finish

2015-08-01

Last updated by the study team

2016-11-23

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 50-90 years old.
• Male or postmenopausal (women who have had no menses for one year)
• Degenerative joint disease of the hip (osteoarthritis) requiring total hip arthroplasty, based on radiologic and clinical impression.

You may not qualify if…

• Any contraindications to use of TPTD.
• Age younger than 50, greater than 90 years old.
• Metabolic bone disease other than osteoporosis.
• History of hyperparathyroidism without surgical correction.
• Unexplained hypercalcemia.
• Paget's disease (or unexplained elevated bone alkaline phosphatase level).
• History of any metastatic cancer or osteosarcoma.
• Prior radiation treatment.
• Secondary hyperparathyroidism due to vitamin D deficiency or renal disease. Active hyperthyroidism or excessive thyroid hormone replacement (with TSH below normal range).

Where it is running

• Helen Hayes Hospital — West Haverstraw, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.